-
-
-
-
-
-
-
Moleculin's Annamycin shows no significant heart toxicity in leukemia study
-
-
-
-
-
-
-
Moleculin launches CEO Corner platform for investor communication
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Moleculin Biotech (MBRX)
-
-
-
-
-
-
-
Moleculin Biotech (MBRX) Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Moleculin Biotech (MBRX)
-
-
-
-
-
-
-
Moleculin Biotech (MBRX) Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia Trial
-
-
-
-
-
-
484,119 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


